Procyon Advisors LLC Has $727,000 Stake in Astrazeneca Plc $AZN

Procyon Advisors LLC raised its stake in shares of Astrazeneca Plc (NYSE:AZN) by 82.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,911 shares of the company’s stock after buying an additional 3,573 shares during the period. Procyon Advisors LLC’s holdings in Astrazeneca were worth $727,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Triumph Capital Management bought a new position in shares of Astrazeneca in the 3rd quarter valued at approximately $25,000. Rakuten Investment Management Inc. acquired a new stake in Astrazeneca in the 3rd quarter worth approximately $31,000. JPL Wealth Management LLC bought a new stake in Astrazeneca during the third quarter worth approximately $35,000. E Fund Management Hong Kong Co. Ltd. boosted its position in Astrazeneca by 144.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock worth $36,000 after purchasing an additional 275 shares during the period. Finally, Abound Wealth Management grew its holdings in Astrazeneca by 1,767.9% during the third quarter. Abound Wealth Management now owns 523 shares of the company’s stock valued at $40,000 after purchasing an additional 495 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Trading Up 0.4%

Shares of AZN stock opened at $184.27 on Tuesday. Astrazeneca Plc has a 12 month low of $122.48 and a 12 month high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. The company has a market cap of $285.79 billion, a PE ratio of 31.74, a price-to-earnings-growth ratio of 1.38 and a beta of 0.32.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were issued a $1.595 dividend. The ex-dividend date of this dividend was Friday, February 20th. This represents a yield of 156.0%. Astrazeneca’s dividend payout ratio is 66.26%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on AZN shares. Morgan Stanley reissued an “overweight” rating and issued a $103.00 price target on shares of Astrazeneca in a research report on Wednesday, December 3rd. Weiss Ratings initiated coverage on shares of Astrazeneca in a research note on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Friday, February 6th. Finally, Guggenheim restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, December 3rd. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $95.75.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.